Table 1.
Relationship between the TRIM44 immunoreactivity and clinicopathological parameters in 129 breast cancer patients. ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; IR, immunoreactivity; SEM, standard error of the mean.
| TRIM44 Status | p-Value | ||
|---|---|---|---|
| Weak IR (n = 62) | Strong IR (n = 67) | ||
| Age (±SEM) | 55.6 ± 1.4 | 52.2 ± 1.3 | 0.044 |
| ≤50 years old | 22 | 34 | 0.081 |
| >50 years old | 40 | 33 | |
| Stage | 0.933 | ||
| I | 31 | 33 | |
| II, III | 31 | 34 | |
| Pathological tumor size | 0.476 | ||
| ≤20 mm | 36 | 43 | |
| >20 mm | 26 | 24 | |
| Lymph node status | 0.131 | ||
| Negative | 44 | 39 | |
| Positive | 18 | 28 | |
| ER status | 0.305 | ||
| Negative | 8 | 5 | |
| Positive | 54 | 62 | |
| PgR status | 0.201 | ||
| Negative | 18 | 13 | |
| Positive | 44 | 54 | |
| HER2 status | 0.353 | ||
| Negative | 51 | 59 | |
| Positive | 11 | 8 | |
| Nuclear grade | 0.033 | ||
| 1 | 42 | 33 | |
| 2, 3 | 20 | 34 | |